Feminizing hormone therapy increases estrogen levels and decreases testosterone levels to induce traditionally female characteristics in the body.

The addition of the hormone progesterone to gender-affirming hormone therapy leads to increased breast growth for transgender people following feminizing hormone therapy. This is demonstrated by an ...

A new study highlights just how flexible the human body can be by demonstrating that in adult transgender women receiving gender-affirming hormone therapy, several key proteins became altered to more ...

THURSDAY, Nov. 6, 2025 (HealthDay News) — Transgender women using estradiol for their transition don’t run an increased risk of heart attack or stroke, a new study says. In fact, their hormone ...

According to the U.S. Census Bureau, about 2.6 million Americans identify as transgender, meaning their gender identity is different from the sex assigned to them at birth. When transgender people ...

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

PARIS — Screening for breast, cervical, and prostate cancer should continue for transgender patients after they transition to their new identity, but the screening methods must be adapted. This was ...

Lenacapavir does not appear to cause any clinically significant effects in the pharmacokinetics of long-acting hormonal contraceptives or gender-affirming hormone therapy, according to a pair of ...

A new study of the longest-acting form of injectable PrEP, lenacapavir, has shown no adverse interactions with hormone therapy for trans women and men. Marketed under the brand name Yeztugo by Gilead ...